Vaccines Analysis
🇺🇸 FDAExpert commentary and market intelligence for pharma strategy teams
Showing 1–12 of 13 articles
Amish Health Beliefs: Vaccines, Costs, and Pharma Strategy Insights
STAT+: RFK Jr.’s second year: Vacancies, not vaccines
Ebola Response Shift: Trump Administration's New Playbook and Pharma Implications
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19
Personalized mRNA Cancer Vaccines: A New Era for Melanoma Treatment
Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus
Trump's Executive Order on Childhood Vaccine Schedules: Impact on Pharmaceutical Companies
CEPI Funds Three Ebola Vaccine Candidates to Accelerate Outbreak Response
Astellas Cuts Costs Amid FDA Review of Moderna Vaccine
Ebola Outbreak: Testing Long-Shot Vaccines Amid Crisis
FDA Shake-Up: Implications for Oncology and Beyond
FDA Approval mRNA Vaccine RSV: Market Impact & Future Outlook